Psychedelics and the Human Receptorome

We currently understand the mental effects of psychedelics to be caused by agonism or partial agonism of 5-HT2A (and possibly 5-HT2C) receptors, and we understand that psychedelic drugs, especially phenylalkylamines, are fairly selective for these two receptors. This manuscript is a reference work on the receptor affinity pharmacology of psychedelic drugs. New data is presented on the affinity of twenty-five psychedelic drugs at fifty-one receptors, transporters, and ion channels, assayed by the National Institute of Mental Health – Psychoactive Drug Screening Program (NIMH-PDSP). In addition, comparable data gathered from the literature on ten additional drugs is also presented (mostly assayed by the NIMH-PDSP). A new method is introduced for normalizing affinity (Ki) data that factors out potency so that the multi-receptor affinity profiles of different drugs can be directly compared and contrasted. The method is then used to compare the thirty-five drugs in graphical and tabular form. It is shown that psychedelic drugs, especially phenylalkylamines, are not as selective as generally believed, interacting with forty-two of forty-nine broadly assayed sites. The thirty-five drugs of the study have very diverse patterns of interaction with different classes of receptors, emphasizing eighteen different receptors. This diversity of receptor interaction may underlie the qualitative diversity of these drugs. It should be possible to use this diverse set of drugs as probes into the roles played by the various receptor systems in the human mind.

[1]  F. Mauler,et al.  Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. , 2002, The Journal of pharmacology and experimental therapeutics.

[2]  P. Giraud,et al.  Interaction of opiates with opioid binding sites in the bovine adrenal medulla: I. Interaction with delta and mu sites. , 1985, Journal of neurochemistry.

[3]  P. Giraud,et al.  Interaction of Opiates with Opioid Binding Sites in the Bovine Adrenal Medulla: I. Interaction with δ and μ Sites , 1985 .

[4]  G. Pasternak,et al.  Opiate binding in calf thalamic membranes: a selective mu 1 binding assay. , 1988, Molecular pharmacology.

[5]  R. Glennon,et al.  Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. , 1983, European journal of pharmacology.

[6]  J. Pomonis,et al.  DiPOA ([8-(3,3-Diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic Acid), a Novel, Systemically Available, and Peripherally Restricted Mu Opioid Agonist with Antihyperalgesic Activity: II. In Vivo Pharmacological Characterization in the Rat , 2004, Journal of Pharmacology and Experimental Therapeutics.

[7]  R. Glennon.  Do classical hallucinogens act as 5-HT2 agonists or antagonists? , 1990, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[8]  G. Pasternak,et al.  Classification of multiple morphine and enkephalin binding sites in the central nervous system. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Bryan L. Roth,et al.  Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. Iwamura,et al.  In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. , 2001, The Journal of pharmacology and experimental therapeutics.

[11]  P P Humphrey,et al.  International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. , 1994, Pharmacological reviews.

[12]  R. Mowbray,et al.  HALLUCINOGENS , 1970, The Medical journal of Australia.

[13]  S. Snyder,et al.  Psychotomimetic opiate receptors labeled and visualized with (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Nichols,et al.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. , 1986, Journal of psychoactive drugs.

[15]  D. E. Nichols,et al.  Serotonin receptors. , 2008, Chemical reviews.

[16]  A. I. Brooks,et al.  Biochemical and pharmacological characterization of mu, delta and kappa 3 opioid receptors expressed in BE(2)-C neuroblastoma cells. , 1994, The Journal of pharmacology and experimental therapeutics.

[17]  N. Darmani.  Further evidence for enigmas in adaptation mechanisms for the DOI-induced behaviors , 1992, Pharmacology Biochemistry and Behavior.

[18]  V. Watts,et al.  Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. , 2000, Journal of medicinal chemistry.

[19]  H. Szeto,et al.  Comparison of [Dmt1]DALDA and DAMGO in Binding and G Protein Activation at μ, δ, and κ Opioid Receptors , 2003, Journal of Pharmacology and Experimental Therapeutics.

[20]  R. Glennon,et al.  Multiple populations of serotonin receptors may modulate the behavioral effects of serotonergic agents. , 1991, Life sciences.

[21]  J. Lameh,et al.  Activity of opioid ligands in cells expressing cloned mu opioid receptors , 2003, BMC pharmacology.

[22]  Arthur Christopoulos,et al.  International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology , 2003, Pharmacological Reviews.

[23]  R. Glennon,et al.  Serotonin receptors and their ligands: A lack of selective agents , 1991, Pharmacology Biochemistry and Behavior.

[24]  F. Ötvös,et al.  Binding characteristics of [3H]14‐methoxymetopon, a high affinity µ‐opioid receptor agonist , 2003, The European journal of neuroscience.

[25]  R. Glennon,et al.  Structure-activity relationships and mechanism of action of hallucinogenic agents based on drug discrimination and radioligand binding studies. , 1986, Psychopharmacology bulletin.

[26]  H. Szeto,et al.  DALDA AND DAMGO IN BINDING AND G PROTEIN ACTIVATION AT MU , DELTA AND KAPPA OPIOID RECEPTORS , 2003 .

[27]  D. E. Nichols,et al.  Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). , 2002, Journal of medicinal chemistry.

[28]  L. Towns,et al.  The head-twitch response in the least shrew (Cryptotis parva) is a 5-HT2− and not a 5-HT1C-mediated phenomenon , 1994, Pharmacology Biochemistry and Behavior.

[29]  B. Roth,et al.  2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. , 2000, Journal of medicinal chemistry.

[30]  P. Schiller,et al.  Synthesis and in vitro opioid activity profiles of DALDA analogues. , 2000, European journal of medicinal chemistry.

[31]  R. Glennon,et al.  Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. , 1984, Life sciences.

[32]  F. Mauler,et al.  3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB1/CB2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects , 2004, Journal of Pharmacology and Experimental Therapeutics.

[33]  G. Griffin,et al.  Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. , 2000, The Journal of pharmacology and experimental therapeutics.

[34]  Paul Ernsberger,et al.  Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. , 2002, Proceedings of the National Academy of Sciences of the United States of America.